1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Co., Ltd.

SMDPY
Sumitomo Pharma Co., Ltd.US flagOther OTC
9.25
USD
- -
- -
4.15BMarket Cap
Sumitomo Pharma Co., Ltd.
SMDPY
(Other OTC)

Recent

price

9.25

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
955.24
881.89
875.22
975.84
934.72
1,014.86
1,027.83
1,175.03
1,155.98
1,215.05
1,298.67
1,409.63
1,398.33
791.76
1,003.91
1,140.97
407.53
Revenue per Share
42.27
21.72
25.28
50.49
38.88
62.16
78.82
134.53
122.39
102.58
141.5
141.99
-187.55
-792.79
59.49
268.99
-622.25
Basic EPS, GAAP
115.51
99.5
100.4
71.45
45.02
99.86
14.31
204.04
90.1
82.5
314.11
44.66
-2.03
-648.45
8.73
- -
-187.98
Free Cash Flow per Basic Share
17.99
17.99
18
18
18
18
18
20
27.99
32.99
27.99
28
28
7.03
0.01
- -
0.02
Dividend per Share
821.98
769.33
776.61
802.56
822.25
877.82
956.88
1,053.2
1,143.22
1,207.49
1,336.74
1,350.67
763.67
-0.67
174.15
456.55
23.02
Book Value per Share
454.85
532.38
510.78
608.46
697.6
588.53
289.35
422.72
572.37
104.12
222.2
200.69
-332.12
-602.33
-504.52
-199.11
-640.04
Tangible Book Value per Share
397
397
397
397
397
397
397
397
397
397
397
397
397
397
397
397
397
Basic Weighted Avg Shares
379,529
350,384
347,732
387,709
371,370
403,205
408,357
466,838
459,267
482,732
515,952
560,035
555,544
314,558
398,832
453,294
161,916
Sales/Revenue/Turnover
34.41
5.82
7.2
10.87
6.27
9.16
9.87
18.89
12.6
17.24
13.8
10.76
-13.86
-112.8
7.45
23.18
-165.74
Operating Margin (%)
44,627
40,232
35,085
26,776
19,226
20,265
12,713
12,887
13,976
17,365
22,673
38,348
41,263
37,765
25,562
- -
19,106
Depreciation Expense
16,796
8,629
10,043
20,060
15,447
24,697
31,316
53,448
48,627
40,753
56,219
56,413
-74,512
-314,969
23,634
106,865
-247,228
Net Income, GAAP
32.95
47.15
44.69
42.2
54.23
37.57
26.8
37.02
25.24
57.21
52.69
51.06
- -
- -
- -
- -
- -
Effective Tax Rate (%)
4.43
2.46
2.89
5.17
4.16
6.13
7.67
11.45
10.59
8.44
10.9
10.07
-13.41
-100.13
5.93
23.58
-152.69
Profit Margin (%)
175,796
228,285
208,607
228,404
244,856
157,658
75,427
138,333
175,094
-132,408
181,648
221,148
9,166
-245,905
12,565
7,752
-174,588
Working Capital
93,000
118,000
95,000
85,000
50,000
28,000
10,000
30,940
27,980
25,020
263,859
243,963
244,128
133,367
258,982
179,056
133,430
LT Debt
323,983
319,227
349,248
398,540
451,021
389,594
412,268
452,723
498,138
635,860
648,178
673,569
406,782
156,136
169,479
292,467
114,244
Total Equity
17.46
2.3
3.01
5.02
2.04
4.57
6.15
11.05
8.17
4.74
3.54
3.11
- -
- -
- -
- -
- -
Return on Invested Capital (%)
3.76
2.02
2.48
4.93
3.84
6.22
7.51
12.49
10.26
6.85
8.76
8.45
- -
- -
- -
- -
- -
Return on Capital (%)
5.22
2.73
3.27
6.39
4.79
7.31
8.59
13.39
11.14
8.73
11.12
10.57
-17.74
- -
- -
85.3
-198.6
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
285,517
- -
255,950
LT Borrowings
133,367
- -
133,430
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
397
- -
397
Market Capitalization
156,248
124,667
249,569

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
269,569
- -
311,929
Cash, Cash Equivalents & STI
36,132
- -
115,911
Accounts Receivable, Net
81,023
- -
66,063
Inventories
115,350
- -
105,637
Total Current Liabilities
515,474
- -
486,517
Payables & Accruals
- -
- -
- -
ST Debt
285,517
- -
255,950
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.91%
-3.24%
72.57%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
44.59%
67.13%
352.17%
Sales/Revenue/Turnover
3.08%
0.96%
13.66%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
75,686
76,956
82,386
79,530
314,558
2025
- -
- -
- -
- -
398,832
2026
- -
- -
- -
- -
453,294

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-97.81
-72.68
-125.77
- -
-792.79
2025
- -
- -
- -
- -
59.49
2026
- -
- -
- -
- -
268.99

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6.89
0.12
0.02
- -
7.03
2025
- -
- -
- -
- -
0.01
2026
- -
- -
- -
- -
- -
Similar Companies
Desh Rakshak Aushdhalaya Ltd. (DESHRAK.BO)
Invion Limited (IVIXF)
INDVR Brands Inc. (IDVR.CN)
Excelsior Biopharma Inc. (6496.TWO)
Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS)
Jiuzhitang Co., Ltd. (000989.SZ)
Business
Sumitomo Pharma Co., Ltd. (SMDPY) develops, manufactures and markets innovative pharmaceuticals and healthcare solutions with a focus on psychiatry and neurology, oncology, regenerative medicine and cell therapy, and other therapeutic areas including diabetes and rare diseases. The company offers prescription drugs such as those for Parkinson's disease, schizophrenia, type 2 diabetes including Ozempic through co-promotion, obesity treatments including Wegovy through recent co-promotion agreements, and iPS cell-derived therapies for conditions like Parkinson's disease; it also provides animal health products, food ingredients and chemical materials. Sumitomo Pharma operates primarily in Japan and the United States, with additional presence in Asia and global research collaborations, from its headquarters in Osaka, Japan, where it was founded in 1897. In recent developments, Sumitomo Pharma entered a co-promotion agreement with Novo Nordisk Pharma in October 2025 for Wegovy, a GLP-1 receptor agonist for obesity treatment in Japan, building on their July 2025 co-promotion of Ozempic for type 2 diabetes; co-promotion activities for Wegovy commence in November 2025. The company sold its pharmaceutical sales business in Asia to Marubeni Corporation in a transaction completed around April 2025, involving a new entity where Marubeni holds a 60% stake valued at approximately 45 billion yen, with an option for the remainder post-2029. In November 2025, Sumitomo Pharma offloaded subsidiaries Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd. to Marubeni Global Pharma as part of ongoing restructuring efforts.

Company News

APIChatGPT

  • businesswire.com

    Sumitomo Pharma America Achieves Key Patient Enrollment Milestone for Pivotal Phase 2 Study of Enzomenib in the Treatment of Relapsed/Refractory Acute Leukemia

  • seekingalpha.com

    Sumitomo Pharma Co., Ltd. (DNPUF) Discusses R&D Progress, Oncology Pipeline, and Advances in Regenerative Medicine and Vaccines Transcript

  • cnbc.com

    Sumitomo Pharma shares plunge 12% despite greenlight for Parkinson's treatment